UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

CLSI NBS08

Newborn Screening for Hemoglobinopathies

active, Most Current
Buy Now
Organization: CLSI
Publication Date: 1 October 2019
Status: active
Page Count: 120
scope:

This guideline focuses on the NBS laboratory analytical processes for detecting SCD and other clinically significant hemoglobin disorders, including basic information about the biological and clinical features of clinically significant hemoglobinopathies detectable through NBS. It also provides information on preanalytical considerations affecting laboratory detection of hemoglobinopathies in NBS, including dried blood spot (DBS) specimen stability considerations. Various NBS procedures for hemoglobinopathy detection are discussed, with details of the methods included in the appendixes following a general template to allow easier comparisons between the different screening technologies. Terminology and reporting recommendations are included, along with other postanalytical NBS activities, including both short-term follow-up (STFU) activities (tracking and confirmatory testing) and long-term follow-up (LTFU) activities (outcome indicators, registries, care coordination, and access to services).

The guideline's overall purpose is to provide sufficient information for worldwide quality NBS process implementation, evaluation, and harmonization. This guideline may also inform policymaking for ensuring quality NBS results. Intended users of this guideline include:

• NBS laboratory and associated follow-up personnel

• Hospital personnel managing newborn DBS specimen collection activities, including:

‒ Newborn DBS specimen collection supplies management

‒ Newborn DBS specimen collection and transmittal process

‒ NBS patient follow-up

‒ NBS recordkeeping

• Medical personnel advising NBS programs and caring for affected newborns

• Manufacturers of laboratory kits and other products intended to be a part of the hemoglobinopathy NBS process

This guideline is not intended to provide:

• Details of confirmatory diagnostic laboratory testing processes

• Information about inappropriate NBS methods, such as solubility testing

• Models or recommendations for parent or provider education or for genetic counseling

Document History

CLSI NBS08
October 1, 2019
Newborn Screening for Hemoglobinopathies
This guideline focuses on the NBS laboratory analytical processes for detecting SCD and other clinically significant hemoglobin disorders, including basic information about the biological and...

References

Advertisement